Table of Contents

Basics of Kcentra ICD 10 PCS

Kcentra is a prescription medicine used to treat the symptoms of Vitamin K Antagonist Reversal. Kcentra may be used alone or with other medications. Kcentra belongs to a class of drugs called Blood Components; Hemostatics. It is not known if Kcentra is safe and effective in children. Its Generic name is Prothrombin Complex Concentrate (Human). Their are specific KCENTRA ICD 10 PCS codes in medical coding which we learn below.

KCENTRA is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.

KCENTRA ICD 10 PCS Coding

As per the coding guidelines the below are ICD 10 PCS codes are used for KCENTRA based on facility.

Use the following specific ICD-10-PCS code when administrating Kcentra for Hospital inpatient setting.

30283B1 – Transfusion of Nonautologous 4-Factor Prothrombin Complex Concentrate into Vein, Percutaneous Approach

Section – 3 Administration

Body system – 0 circulatory

Root Operation – 2 Transfusion

Body system/region- 8 Vein

Approach – 3 Percutaneous

Substance – B 4-Factor Prothrombin Complex Concentrate

Qualifier – 1 Nonautologous

Effective July 1, 2021, the Centers for Medicare and Medicaid Services (CMS) has established a permanent, product-specific HCPCS code for Kcentra.^®21For services on or after July 1, 2021, use the permanent J-code when administrating Kcentra

J7168 – Prothrombin complex concentrate (human), Kcentra, per IU of Factor IX activity

Kcentra ICD 10 PCS – Warning

ARTERIAL AND VENOUS THROMBOEMBOLIC COMPLICATIONS

Patients being treated with Vitamin K antagonists (VKA) therapy have underlying disease states that predispose them to thromboembolic events. Potential benefits of reversing VKA should be weighed against the potential risks of thromboembolic events (TE), especially in patients with the history of a thromboembolic event. Resumption of anticoagulation should be carefully considered as soon as the risk of thromboembolic events outweighs the risk of acute bleeding.

Both fatal and non-fatal arterial and venous thromboembolic complications have been reported with Kcentra in clinical trials and post marketing surveillance. Monitor patients receiving Kcentra for signs and symptoms of thromboembolic events.

Kcentra was not studied in subjects who had a thromboembolic event, myocardial infarction, disseminated intravascular coagulation, cerebral vascular accident, transient ischemic attack, unstable angina pectoris, or severe peripheral vascular disease within the prior 3 months. Kcentra may not be suitable in patients with thromboembolic events in the prior 3 months.